Bioxytran Inc BIXT

Healthcare Biotechnology

Bioxytran, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The Company's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with an intended application, which includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiary, Pharmalectin Inc., is focused on the development, manufacturing, and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin Inc. has developed a method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Its lead drug candidate, named ProLectin-Rx, is a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin.

OTCQB:BIXT - Post by User

Bioxytran Inc

<< Previous

Bullboard Posts

Next >>

Post by khandaanita4444on Sep 11, 2023 9:44am

54 Views

Post# 35629128

$BIXT - Pioneering Clinical Biotechnology Solutions.

Bioxytran, Inc. ($BIXT) spearheads the charge in clinical biotechnology, focusing its efforts on the development of groundbreaking therapies poised to address unmet medical needs in virology, degenerative disease, and hypoxia. There are 132.03 million shares in circulation.

<< Previous

Bullboard Posts

Next >>

The top 10 artificial intelligence penny stocks